1 *Brief Rapid Reports*

2 **Association of antihypertensive agents with the risk of in-hospital death in patients with**

3 **Covid-19**

4 Short title: antihypertensive agents and mortality in Covid-19

5

6 Laurent Chouchana PharmD PhD¹, Nathanaël Beeker PhD², Nicolas Garcelon MD PhD^{3,4},

7 Bastien Rance MD PhD^{3,5}, Nicolas Paris PhD⁶, Elisa Salamanca⁶, Elisabeth Polard PharmD⁷,

8 Anita Burgun MD PhD^{3,5,8}, Jean-Marc Treluyer MD PhD^{1,2} and Antoine Neuraz, MD^{3,8}

9 On behalf of AP-HP / Universities / Inserm COVID-19 research collaboration; AP-HP Covid CDR

10 Initiative and 'Entrepôt de Données de Santé' AP-HP consortium.

11

12 ¹ Centre Régional de Pharmacovigilance, Département de Pharmacologie, Hôpital Cochin, AP-
13 HP.Centre – Université de Paris. Paris, France.

14 ² Unité de Recherche clinique, Hôpital Cochin, AP-HP.Centre – Université de Paris. Paris, France.

15 ³ Centre de Recherche des Cordeliers, INSERM UMRS_1138 Team 22, Université de Paris. Paris,
16 France.

17 ⁴ Institut Imagine, Université de Paris. Paris, France.

18 ⁵ Département d'informatique médicale, Hôpital Européen Georges Pompidou, AP-HP.Centre –
19 Université de Paris. Paris, France.

20 ⁶ Département Web Innovation Données (WIND), Direction des systèmes d'information, AP-HP.
21 Paris, France.

22 ⁷ Centre Régional de Pharmacovigilance, pharmacoépidémiologie et information sur le médicament,
23 CHU Rennes. Rennes, France.

24 ⁸ Département d'informatique médicale, Hôpital Necker-Enfants Malades, AP-HP.Centre –
25 Université de Paris. Paris, France.

26

27 **Corresponding author:** Dr Laurent Chouchana (ORCID 0000-0002-9626-3571).

28 Address: Centre Régional de Pharmacovigilance, Hôpital Cochin. 27 rue du Faubourg Saint-Jacques,
29 75014 Paris, France. Email: laurent.chouchana@aphp.fr. Tel +33158413479 / Fax +33158413370 /
30 Twitter @LChouchana

31

32 **Word count:** 1284 **Number of table:** 1 **Number of figure:** 1 **References:** 16

33 **ABSTRACT**

34 In this retrospective multicenter cohort study, we aimed to investigate the association between
35 antihypertensive agent exposure and in-hospital mortality in patients with Covid-19. Of 8,078
36 hospitalized patients for Covid-19, 3,686 (45.6%) had hypertension including 2043 (55.4%)
37 patients exposed to a renin-angiotensin-aldosterone inhibitors (RAASi), 1624 (44.1%) to
38 calcium channel blockers (CCB) and 1154 (37.7%) to beta-blockers. Overall in-hospital 30-
39 day mortality was 23.1%. Compared to non-users, the risk of mortality was lower in CCB
40 (aOR, 0.83 [0.70-0.99]) and beta-blockers users (aOR, 0.80 [0.67-0.95]), and not different in
41 RAASi users. These findings support the continuation of antihypertensive agents in patients
42 with Covid-19.

43

44

45 **Keywords:** Covid-19; SARS-CoV-2; Renin-angiotensin-aldosterone inhibitors; drug safety;
46 calcium channel blockers

47

48 INTRODUCTION

49 The coronavirus disease-2019 (Covid-19), due to the novel severe acute respiratory syndrome
50 coronavirus-2 (SARS-CoV-2) is a global pandemic representing a major treat to global health.
51 Data from several cohorts have shown that age and cardiovascular comorbidities, including
52 hypertension, were among the main determinants of severe disease.^{1,2} As SARS-CoV-2 uses
53 the angiotensin-converting enzyme 2 (ACE2) receptor as an entrance door into cells,
54 questions have been raised about the role of the renin-angiotensin-aldosterone system (RAAS)
55 activity on Covid-19 pathophysiology.³ RAAS inhibitors directly acts on RAAS in two
56 different ways, both leading to ACE2 upregulation.³ On the contrary, some authors have
57 hypothesized that the use of RAAS inhibitors may protect against acute lung injury caused by
58 angiotensin II accumulation.⁴ Therefore, since these drugs such as ACE inhibitors (ACEi) or
59 angiotensin receptor blockers (ARB) are common treatments for hypertension, controversies
60 about their role on Covid-19 severity have been raised. To date, scientific societies have
61 advised against their discontinuation in patients with hypertension, until robust clinical
62 evidence is available.⁵ Previous reports showed that RAAS inhibitors do not increase the risk
63 of severe or fatal outcome in Covid-19 patients.^{1,6,7} The role of other antihypertensive agents
64 is unclear. However, these analyses are retrospective and additional data are needed to
65 ascertain the beneficial or harmful effect of antihypertensive agents on Covid-19 mortality.
66 In order to provide additional information, we performed a multicenter retrospective cohort
67 study in patients hospitalized for Covid-19 in Greater Paris area, France.

68

69

70 **METHODS**

71 **Study population**

72 This retrospective cohort study was conducted using the Assistance Publique-Hopitaux de
73 Paris (AP-HP) Health Data Warehouse ('Entrepôt de Données de Santé (EDS)'
74 <https://eds.aphp.fr/>). This data-warehouse contains electronic health records (EHRs) of all
75 inpatients from the 39 greater Paris university hospitals. Adult patients having at least one
76 SARS-CoV-2 positive PCR test and hospitalized between February 1st and May 15th, 2020
77 have been included. Patients having a PCR test performed more than fourteen days after
78 hospitalization have been excluded considering they were very likely to be nosocomial
79 infection. Patients have been followed at least 30 days after inclusion (date of first PCR test
80 positive). The Institutional Review Board of the AP-HP Health Data Warehouse approved this
81 study on April 7th, 2020 (CSE-20-18_COVID19).

83 **Comorbidities and drug exposure**

84 Hypertension as well as other comorbidities have been retrieved in EHRs using specific codes
85 from the International Classification of Diseases 10th version, combined with natural language
86 processing (regular expressions) as previously described, within the six months previous to
87 the hospital stay for Covid-19 (Suppl Table S1).⁸ Antihypertensive agent exposure have been
88 identified in EHRs at admission of the hospital stay for Covid-19 and within the six previous
89 months, using both specific Anatomical Therapeutic Chemical classification (ATC) codes and
90 deep learning algorithm on clinical narratives as previously described (Suppl Table S2).⁸ As
91 described in Neuraz et al.⁸, we extracted drug mentions and their attributes (dose, frequency,
92 duration, route, condition) using a deep-learning pipeline based on fine-tuned multilingual
93 embeddings and bidirectional long-short term memory units combined with conditional
94 random fields.⁹ The drug mentions were then normalized to ATC using exact string matching.

95

96 **Statistical analysis**

97 The primary outcome was all-cause 30-day in-hospital mortality. We assessed the association
98 between antihypertensive agent class exposure and primary outcome using a multivariate
99 logistic regression. Analyses were adjusted on age, sex and main chronic diseases to take into
100 account confounding factors known to be associated with Covid-19 mortality. Data are
101 presented as median (interquartile range [IQR]) and numbers (%). The results of the logistic
102 regression model are presented as crude odds-ratio (OR) or adjusted OR (aOR) and their 95%
103 confidence interval ([95% CI]). All analyses were performed using R statistical software.

104

105

106 RESULTS

107 In Greater Paris University hospitals, 8,078 patients had been hospitalized for Covid-19
 108 between February 1st and May 15th 2020, among which 1,531 (19.0%) died within 30 days.
 109 Among hospitalized patients, 3,686 (45.6%) had hypertension and were included in the study.
 110 In this population, median age was 75.4 (21.5) years and 57.1 % were male (Table 1).
 111 Regarding antihypertensive agents, the main pharmacological classes used were RAAS
 112 inhibitors (n=2043, 55.4%), calcium channel blockers (CCB) (n=1624, 44.1%), beta-blockers
 113 (n=1154, 37.7%), and centrally acting sympatholytics (n=172, 4.7%). More specifically for
 114 RAAS inhibitors, ARB and ACEi were used in 1154 (31.3%) and 998 (27.1%) patients,
 115 respectively, and no patient received a renin-inhibitor. In 826 patients (22.4%) no
 116 antihypertensive treatment was identified.
 117 In total, there were 853 (23.1%) all-cause in-hospital 30-day deaths. Patients who died were
 118 older and there were more likely to be men, compared to survivors. They also had chronic
 119 diseases more frequently, except for respiratory diseases and obesity. The risk of mortality
 120 was lower in CCB (aOR, 0.83 [0.70-0.99]) and beta-blockers users (aOR, 0.80 [0.67-0.95]),
 121 and non-significant in ARB (aOR, 0.88 [0.72-1.06]) and ACEi users (aOR, 0.83 [0.68-1.02]),
 122 compared to non-users (Figure 1, Suppl. Table S3).

123

124

125 **DISCUSSION**

126 This study, one of the largest multicenter retrospective to date on more than 3600 hospitalized
127 Covid-19 patients with hypertension, provides two main findings. First, based on more than
128 2,000 patients exposed to RAAS inhibitors, there is no association with the use of ACEi or
129 ARB and the risk of in-hospital death. Second, there is a significant protective effect of
130 calcium-channel blockers (CCB) or beta-blocker use on the risk of death in hypertensive
131 patients with Covid-19.

132 Hypertension and cardiovascular comorbidities have been previously reported as risk factors
133 for severe disease and fatal outcome.^{1,10,11} The underlying pathogenic mechanisms of these
134 comorbidities remain unclear and may involve the RAAS as being a double-edged sword. On
135 one hand, RAAS inhibitors increase the expression of ACE2, which could promote virus
136 entry.³ On the other hand, RAAS inhibitors, especially ARB, could reverse deleterious effects
137 of unopposed angiotensin II accumulation resulting from ACE2 down-regulation associated to
138 SARS-CoV-2 entry in cells.^{4,12} Clinical evidence based on a large study including 12,594
139 tested patients for SARS-CoV-2 showed no increase of likelihood to have a positive test
140 among RAAS users.¹³ Furthermore, in line with our findings, a meta-analysis on four
141 retrospective studies that include 921 ACEi or ARB users found no difference in risk of death
142 compared to non-users (OR, 0.88 [0.68-1.14]).¹⁴

143 In our study, we found that CCB and beta-blockers were more frequently used in survivors
144 (OR 0.83 [0.70-0.99] and 0.80 [0.67-0.95], respectively) than in non-survivors. These findings
145 were statistically significant. Previous Covid-19 cohort studies did not find any beneficial or
146 deleterious effect of CCB use on Covid-19 severity or mortality.^{7,15} However, these studies
147 included few CCB users and were probably lacking power. Recently, an *in vitro* study on an
148 emerging porcine coronavirus showed that CCB could prevent from infection and intracellular
149 calcium homeostasis dysregulation.¹⁶ Regarding beta-blockers, one could hypothesize that

they can counteract deleterious sympathetic activation during the SARS-CoV-2 induced cytokine storm and severe disease. Further clinical data are needed to explore these early findings.

Our study has some limitations. First, in this retrospective observational design on hospitalized Covid-19 patients, hypertension or antihypertensive exposure could have affected the chance of hospitalization, which may limit the generalizability of our results. Second, although analyses were adjusted on major comorbidities, some unmeasured or unknown confounders may have not been ruled out, including indication bias. Finally, ascertainment of medication use from EHRs may not capture all drug prescriptions and not reflect actual drug exposure. However, considering antihypertensive agents are chronic treatments, we consider exposure to these drugs up to six months prior to hospitalization for Covid-19.

CONCLUSION

In summary, we did not find any association between the use of RAAS inhibitors and the risk of in-hospital death in Covid-19 patients with hypertension. Interestingly we found a reduced mortality among CCB and beta-blockers users. Further studies are needed to confirm this protective role. Our findings, such as previous reports, support the continuation of antihypertensive agents in Covid-19 patients, in line with the current guidelines.

170 **DECLARATIONS**

171 **Acknowledgments**

172 The authors thank the EDS AP-HP Covid consortium integrating the AP-HP Health Data
173 Warehouse team as well as all the AP-HP staff and volunteers who contributed to the
174 implementation of the EDS-Covid database and operating solutions for this database.

175

176 **Declaration of interests**

177 The authors declare no conflicting interests.

178

179 **Funding**

180 This work was supported by State funding from The French National Research Agency
181 (ANR) under “Investissements d’Avenir” programs (Reference: ANR-10-IAHU-01) and
182 ANR PractikPharma grant (ANR-15-CE23-0028).

183

184 **Author contribution statement**

185 Study design: LC, AN

186 Data management and database build process: NG, BR, NP, ES

187 Statistical analysis: NB, AN

188 Result interpretation: LC, AN

189 Draft the manuscript: LC

190 Critically review the manuscript: LC, AN, EP, AB, JMT

191 Approved the manuscript: LC, NB, NG, BR, NP, ES, EP, AB, JMT, AN

192

193 **Data Availability Statement**

194 Data available on request. The data underlying this article will be shared on reasonable
195 request to the corresponding author.

196

197 **Collaborators**

198 **AP-HP/Universities/INSERM COVID-19 Research Collaboration; AP-HP COVID CDR**

199 **Initiative** Collaborators: Pierre-Yves ANCEL, Alain BAUCHET, Nathanaël BEEKER, Vincent

200 BENOIT, Mélodie BERNAUX, Ali BELLAMINE, Romain BEY, Aurélie BOURMAUD,

201 Stéphane BREANT, Anita BURGUN, Fabrice CARRAT, Charlotte CAUCHETEUX, Julien

202 CHAMP, Sylvie CORMONT, Christel DANIEL, Julien DUBIEL, Catherine DUCLOAS, Loic

203 ESTEVE, Marie FRANK, Nicolas GARCELON, Alexandre GRAMFORT, Nicolas GRIFFON,

204 Olivier GRISEL, Martin GUILBAUD, Claire HASSEN-KHODJA, François HEMERY, Martin

205 HILKA, Anne Sophie JANNOT, Jerome LAMBERT, Richard LAYESE, Judith LEBLANC, Léo

206 LEBOUTER, Guillaume LEMAITRE, Damien LEPROVOST, Ivan LERNER, Kankoe LEVI

207 SALLAH, Aurélien MAIRE, Marie-France MAMZER, Patricia MARTEL, Arthur MENSCH,

208 Thomas MOREAU, Antoine NEURAZ, Nina ORLOVA, Nicolas PARIS, Bastien RANCE,

209 Hélène RAVERA, Antoine ROZES, Elisa SALAMANCA, Arnaud SANDRIN, Patricia SERRE,

210 Xavier TANNIER, Jean-Marc TRELUYER, Damien VAN GYSEL, Gaël VAROQUAUX, Jill

211 Jen VIE, Maxime WACK, Perceval WAJSBURT, Demian WASSERMANN, Eric ZAPLETAL.

212

213

214

215 REFERENCES

216

- 217 1. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, Li Q, Li W, Yang S, Zhao X, Zhao
218 Y, Wang H, Liu Y, Yin Z, Zhang R, Wang R, Yang M, Hui C, Wijns W, McEvoy JW,
219 Soliman O, Onuma Y, Serruys PW, Tao L, Li F. Association of hypertension and
220 antihypertensive treatment with COVID-19 mortality: a retrospective observational
221 study. *Eur Heart J* 2020;**41**:2058–2066.
- 222 2. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui
223 DSC, Du B, Li L-J, Zeng G, Yuen K-Y, Chen R-C, Tang C-L, Wang T, Chen P-Y,
224 Xiang J, Li S-Y, Wang J-L, Liang Z-J, Peng Y-X, Wei L, Liu Y, Hu Y-H, Peng P, Wang
225 J-M, Liu J-Y, Chen Z, et al. Clinical Characteristics of Coronavirus Disease 2019 in
226 China. *N Engl J Med* 2020;**382**:1708–1720.
- 227 3. Brojakowska A, Narula J, Shimony R, Bander J. Clinical Implications of SARS-CoV-2
228 Interaction With Renin Angiotensin System: JACC Review Topic of the Week. *J Am*
229 *Coll Cardiol* Journal of the American College of Cardiology; 2020;**75**:3085–3095.
- 230 4. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug*
231 *Dev Res* 2020;**81**:537–540.
- 232 5. American Heart Association (AHA), Heart Failure Society of America, Heart Failure
233 Society of America (HFSA), American College of Cardiology (ACC). Patients taking
234 ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise
235 advised by their physician. Am. Heart Assoc. [https://newsroom.heart.org/news/patients-](https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician)
236 [taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-](https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician)
237 [otherwise-advised-by-their-physician](https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician) (20 July 2020)
- 238 6. Abajo FJ de, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A,
239 Laredo L, Laosa O, Centeno-Soto GA, Ángeles Gálvez M, Puerro M, González-Rojano
240 E, Pedraza L, Pablo I de, Abad-Santos F, Rodríguez-Mañas L, Gil M, Tobías A,
241 Rodríguez-Miguel A, Rodríguez-Puyol D, MED-ACE2-COVID19 study group. Use of
242 renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring
243 admission to hospital: a case-population study. *Lancet Lond Engl* 2020;**395**:1705–1714.
- 244 7. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System
245 Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for
246 Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol*
247 2020;**5**:1–6.
- 248 8. Neuraz A, Lerner I, Digan W, Paris N, Tsopra R, Rogier A, Baudoin D, Cohen KB,
249 Burgun A, Garcelon N, Rance B, AP-HP/Universities/INSERM COVID-19 Research
250 Collaboration; AP-HP COVID CDR Initiative. Natural Language Processing for Rapid
251 Response to Emergent Diseases: Case Study of Calcium Channel Blockers and
252 Hypertension in the COVID-19 Pandemic. *J Med Internet Res* 2020;**22**:e20773.
- 253 9. Lample G, Ballesteros M, Subramanian S, Kawakami K, Dyer C. Neural Architectures
254 for Named Entity Recognition. *Proceedings of the 2016 Conference of the North*
255 *American Chapter of the Association for Computational Linguistics: Human Language*

- 256 *Technologies* San Diego, California: Association for Computational Linguistics; 2016. p.
257 260–270.
- 258 10. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang
259 T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q.
260 Clinical characteristics of 113 deceased patients with coronavirus disease 2019:
261 retrospective study. *BMJ* 2020;**368**:m1091.
- 262 11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L,
263 Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk
264 factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
265 retrospective cohort study. *Lancet Lond Engl* 2020;**395**:1054–1062.
- 266 12. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD.
267 Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J*
268 *Med* Massachusetts Medical Society; 2020;**382**:1653–1659.
- 269 13. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A,
270 Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y,
271 Ogedegbe G, Hochman JS. Renin-Angiotensin-Aldosterone System Inhibitors and Risk
272 of Covid-19. *N Engl J Med* 2020;**382**:2441–2448.
- 273 14. Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A,
274 Manfredini R, Mantovani LG, Manzoli L. Treatment with ACE inhibitors or ARBs and
275 risk of severe/lethal COVID-19: a meta-analysis. *Heart Br Card Soc* 2020;
- 276 15. Fosbøl EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, Schou M,
277 Phelps M, Gislason GH, Gerds TA, Torp-Pedersen C, Køber L. Association of
278 Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With
279 COVID-19 Diagnosis and Mortality. *JAMA* 2020;
- 280 16. Bai D, Fang L, Xia S, Ke W, Wang J, Wu X, Fang P, Xiao S. Porcine deltacoronavirus
281 (PDCoV) modulates calcium influx to favor viral replication. *Virology* 2020;**539**:38–48.

282

283

284 TABLE

285 **Table 1. Patient characteristics**

	All patients	Patients with hypertension		
	(N=8078)	All (N=3686)	Non survivors (N=853)	Survivors (N=2833)
Age – years, median (IQR)	68 (25.9)	75.4 (21.5)	82.1 (16.3)	72.9 (22.2)
Age – distribution				
18-44 years	1020 (12.6%)	123 (3.3%)	5 (0.6%)	118 (4.2%)
45-64	2544 (31.5%)	876 (23.8%)	83 (9.7%)	793 (28%)
65-74	1662 (20.6%)	813 (22.1%)	165 (19.3%)	648 (22.9%)
75-84	1457 (18%)	919 (24.9%)	264 (30.9%)	655 (23.1%)
> 85	1395 (17.3%)	955 (25.9%)	336 (39.4%)	619 (21.8%)
Sex				
Female	3291 (40.7%)	1583 (42.9%)	330 (38.7%)	1253 (44.2%)
Male	4787 (59.3%)	2103 (57.1%)	523 (61.3%)	1580 (55.8%)
Chronic diseases				
Hypertension	3686 (45.6%)	3686 (100%)	853 (100%)	2833 (100%)
Chronic kidney disease	1644 (20.4%)	1407 (38.2%)	384 (45%)	1023 (36.1%)
Cerebrovascular disease	1511 (18.7%)	1209 (32.8%)	309 (36.2%)	900 (31.8%)
Cardiovascular disease	1762 (21.8%)	1438 (39%)	378 (44.3%)	1060 (37.4%)
Cardiac failure	1099 (13.6%)	949 (25.7%)	261 (30.6%)	688 (24.3%)
Diabetes	2220 (27.5%)	1730 (46.9%)	404 (47.4%)	1326 (46.8%)
Respiratory disease	1427 (17.7%)	944 (25.6%)	162 (19.0%)	782 (27.6%)
Obesity	1851 (22.9%)	1072 (29.1%)	239 (28.0%)	833 (29.4%)
Malignancies	1803 (22.3%)	1286 (34.9%)	324 (38.0%)	962 (34.0%)
Antihypertensive drugs				
RAAS inhibitors	2720 (33.7%)	2043 (55.4%)	441 (51.7%)	1602 (56.5%)
ARB	1520 (18.8%)	1154 (31.3%)	250 (29.3%)	904 (31.9%)
ACEi	1337 (16.6%)	998 (27.1%)	214 (25.1%)	784 (27.7%)
CCB	2210 (27.4%)	1624 (44.1%)	340 (39.9%)	1284 (45.3%)
Beta-blockers	1920 (23.8%)	1389 (37.7%)	315 (36.9%)	1074 (37.9%)
Centrally acting sympatholytics	259 (3.2%)	172 (4.7%)	35 (4.1%)	137 (4.8%)
No antihypertensive drug	3982 (49.3%)	826 (22.4%)	229 (26.8%)	597 (21.1%)

286

287 These groups are not exclusive and one patient can be exposed to more than one

288 pharmacological class. Non-survivors are considered in relation with in-hospital 30-day

289 mortality.

290 ARB: angiotensin II receptor blockers; ACEi: angiotensin-converting enzyme inhibitors;

291 CCB: calcium channel blockers.

292

293 **FIGURE LEGEND**

294

295 **Figure 1. In-hospital 30-day mortality in hypertensive patients with Covid-19 according**

296 **to drug exposure**

297

298 These groups are not exclusive and one patient can be exposed to more than one

299 pharmacological class. Analyses have been adjusted on age, sex and main chronic diseases

300 (i.e. hypertension, chronic kidney disease, cerebrovascular disease, cardiovascular disease,

301 cardiac failure, diabetes, respiratory disease, obesity and malignancies).

302 ARB: angiotensin II receptor blockers; ACEi: angiotensin-converting enzyme inhibitors;

303 CCB: calcium channel blockers

304

	Crude OR (95% CI)	Adjusted OR (95% CI)
ARB	0.87 [0.73-1.03]	0.88 [0.72-1.06]
ACEi	0.89 [0.75-1.06]	0.83 [0.68-1.02]
CCB	0.80 [0.68-0.94]	0.83 [0.70-0.99]
Beta-blockers	0.96 [0.82-1.12]	0.80 [0.67-0.95]
Centrally acting sympatholytics	0.80 [0.54-1.17]	1.20 [0.78-1.81]